Lux Peptides

Lux Peptides RETA (retatrutide) research vial, lyophilised powder
Certificate of Analysis for RETA (retatrutide) 10 mg, independent laboratory test report
Certificate of Analysis for RETA (retatrutide) 20 mg, independent laboratory test report
Certificate of Analysis for RETA (retatrutide) 40 mg, independent laboratory test report

RETA

Price range: £26.99 through £119.99

Research-grade retatrutide, supplied as lyophilised powder in 10 mg, 20 mg and 40 mg vials. For laboratory research use only. Not for human or animal consumption.

Shipped by Royal Mail, packed with ice packs to keep your order cool in transit. UK delivery £3.99.

SKU: RT-RETA
Category: ,
Brands:

Research reference

RETA

Investigational, not approved

Retatrutide (LY3437943) is an investigational single peptide that acts on three receptors: GIP, GLP-1 and glucagon. It is supplied as a lyophilised powder for laboratory research applications only.

Molecular information

Type

GIP/GLP-1/glucagon receptor agonist

Length

39 amino acids

Formula

C221H342N46O68

Weight

4731.4 g/mol

CAS

2381089-83-2

Form

Lyophilised powder

Vial sizes

10 mg / 20 mg / 40 mg

Classification

Incretin mimetic

Research overview

Retatrutide was developed by Eli Lilly as a triple hormone receptor agonist. Adding glucagon receptor activity to GIP and GLP-1 activity is intended to raise energy expenditure and reduce liver fat, alongside the appetite and glucose effects of incretin signalling. Research focuses on how the three receptor pathways interact in metabolic regulation.

Common research focus areas

  • Triple receptor agonism
  • Energy expenditure models
  • Hepatic fat research
  • Glycaemic control and body weight studies

Laboratory research use only

This product is supplied strictly for laboratory research use. It is not a medicine, food, cosmetic, or dietary supplement, and is not for human or animal consumption. Any use outside a documented laboratory research protocol is prohibited.

Handling

For laboratory use, reconstitute with a sterile diluent appropriate to the research protocol, introducing the diluent slowly against the vial wall to minimise peptide degradation. Do not shake.

Published research

  • LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of conceptCoskun T et al. · Cell Metabolism · 2022 · DiscoveryPMID 35985340
  • Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 TrialJastreboff AM et al. · New England Journal of Medicine · 2023 · Randomised controlled trialPMID 37366315
  • Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USARosenstock J et al. · The Lancet · 2023 · Randomised controlled trialPMID 37385280

Evidence status

Retatrutide is an investigational compound. Published human data come mainly from phase 2 trials, with a phase 3 programme under way. It has not been approved as a medicine by the MHRA, EMA or FDA.

Additional information

Vial Size

10 mg, 20 mg, 40 mg

Related products